- Home
- DIAX vs SEPN Comparison
DIAX vs SEPN Comparison
Compare DIAX & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- SEPN
- Stock Information
- Founded
- DIAX 2005
- SEPN 2022
- Country
- DIAX United States
- SEPN United States
- Employees
- DIAX N/A
- SEPN N/A
- Industry
- DIAX Finance Companies
- SEPN
- Sector
- DIAX Finance
- SEPN
- Exchange
- DIAX Nasdaq
- SEPN NYSE
- Market Cap
- DIAX 516.0M
- SEPN 453.2M
- IPO Year
- DIAX N/A
- SEPN 2024
- Fundamental
- Price
- DIAX $13.64
- SEPN $10.41
- Analyst Decision
- DIAX
- SEPN Buy
- Analyst Count
- DIAX 0
- SEPN 4
- Target Price
- DIAX N/A
- SEPN $27.00
- AVG Volume (30 Days)
- DIAX 96.6K
- SEPN 559.2K
- Earning Date
- DIAX 01-01-0001
- SEPN 08-15-2025
- Dividend Yield
- DIAX 7.93%
- SEPN N/A
- EPS Growth
- DIAX N/A
- SEPN N/A
- EPS
- DIAX N/A
- SEPN N/A
- Revenue
- DIAX N/A
- SEPN $977,000.00
- Revenue This Year
- DIAX N/A
- SEPN N/A
- Revenue Next Year
- DIAX N/A
- SEPN $526.96
- P/E Ratio
- DIAX N/A
- SEPN N/A
- Revenue Growth
- DIAX N/A
- SEPN 108.76
- 52 Week Low
- DIAX $12.80
- SEPN $4.17
- 52 Week High
- DIAX $15.12
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- DIAX 34.64
- SEPN N/A
- Support Level
- DIAX $13.64
- SEPN N/A
- Resistance Level
- DIAX $13.92
- SEPN N/A
- Average True Range (ATR)
- DIAX 0.12
- SEPN 0.00
- MACD
- DIAX -0.06
- SEPN 0.00
- Stochastic Oscillator
- DIAX 1.56
- SEPN 0.00
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.